Cipher Pharmaceuticals(OTC) CPHRF

Cipher Pharmaceuticals Inc. is a specialized pharmaceutical company based in Canada, focusing on developing and marketing innovative therapies. The company offers a diverse portfolio of products aimed at addressing various medical conditions, including severe acne and impetigo.

Products and Services

• Epuris, an isotretinoin formulation for severe acne
• Ozenoxacin, for managing impetigo in adults and children
• Actikerall, for treating actinic keratosis

Growth Outlook

• Development pipeline includes innovative compounds targeting significant medical needs
• Strong market demand for existing products supports revenue growth
• Strategic partnerships may enhance product distribution and market reach

Financial Highlights

• Q2 2026 revenue of $11.76 million, reflecting consistent sales performance
• Net income of $3.91 million in Q2 2026, showcasing profitability
• TTM net profit margin of 58.81%, indicating strong operational efficiency

Cipher Pharmaceuticals Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic medications. The company has established a solid reputation for its innovative products, which cater to unmet medical needs. The diverse product portfolio includes treatments for severe acne, impetigo, and actinic keratosis, among others. The growth outlook for Cipher Pharmaceuticals is promising, driven by a robust development pipeline that includes several innovative compounds. These products are designed to address significant medical conditions, which may lead to increased market demand. Additionally, the company is well-positioned to leverage strategic partnerships that could enhance its distribution capabilities and expand its market reach. Recent financial performance highlights the company's stability and profitability. In the second quarter of 2026, Cipher reported revenue of $11.76 million, demonstrating consistent sales performance. The net income for the same period was $3.91 million, reflecting the company's ability to maintain profitability. Furthermore, the trailing twelve-month net profit margin of 58.81% underscores the operational efficiency and financial health of the organization. Overall, Cipher Pharmaceuticals Inc. presents a compelling opportunity for potential investors interested in the pharmaceutical sector, particularly in companies focused on innovative therapies and strong financial performance.